Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar; and CHS-131, a once-daily oral drug candidate for non-alcoholic steatohepatitis and other metabolic conditions. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
IPO Year: 2014
Exchange: NASDAQ
Website: coherus.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/16/2024 | $4.00 → $1.50 | Buy → Neutral | UBS |
| 11/17/2023 | $11.00 | Outperform | Robert W. Baird |
| 11/8/2023 | Buy → Hold | Maxim Group | |
| 7/24/2023 | $12.00 | Buy | Citigroup |
| 5/1/2023 | $24.00 | Buy | Truist |
| 3/28/2023 | $11.00 | Neutral → Buy | UBS |
| 6/14/2022 | $7.00 | Neutral | UBS |
| 3/7/2022 | $15.00 | Overweight → Neutral | JP Morgan |
| 11/9/2021 | $36.00 → $30.00 | Buy | HC Wainwright & Co. |
| 7/23/2021 | $26.00 → $36.00 | Buy | HC Wainwright & Co. |
Baird analyst Colleen Kusy maintains Coherus BioSciences (NASDAQ:CHRS) with a Outperform and lowers the price target from $9 to $8.
HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $12 price target.
Truist Securities analyst Robyn Karnauskas maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price target from $8 to $7.
HC Wainwright & Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and raises the price target from $11 to $12.
Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.24) by 33.33 percent. This is a 57.33 percent increase over losses of $(0.75) per share from the same period last year. The company reported quarterly sales of $77.063 million which missed the analyst consensus estimate of $80.248 million by 3.97 percent. This is a 137.58 percent increase over sales of $32.436 million the same period last year.
New $38.7 million term loan with a May 2029 maturity $37.5 million royalty monetization financing based on future sales of LOQTORZI and UDENYCA
4 - Coherus BioSciences, Inc. (0001512762) (Issuer)
4 - Coherus BioSciences, Inc. (0001512762) (Issuer)
4 - Coherus BioSciences, Inc. (0001512762) (Issuer)
4 - Coherus BioSciences, Inc. (0001512762) (Issuer)
3 - Coherus BioSciences, Inc. (0001512762) (Issuer)
4 - Coherus BioSciences, Inc. (0001512762) (Issuer)
4 - Coherus BioSciences, Inc. (0001512762) (Issuer)
4 - Coherus BioSciences, Inc. (0001512762) (Issuer)
4 - Coherus BioSciences, Inc. (0001512762) (Issuer)
4 - Coherus BioSciences, Inc. (0001512762) (Issuer)
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday, November 6, 2024. Starting at 5:00 p.m. ET on November 6, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Wednesday, November 6, 2024, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through
– Net revenue of $65.0 million in Q2 2024 – – CHS-114 Phase 1 Study Recruitment Continues into Expansion Cohorts in Head and Neck Cancer in Combination with LOQTORZI – – Bryan McMichael Appointed as Chief Financial Officer – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS), today reported financial results for the quarter ended June 30, 2024 and recent business highlights: RECENT BUSINESS HIGHLIGHTS UDENYCA® RESULTS UDENYCA net product sales were $50.9 million in Q2 2024, an increase of 19% compared to $42.7 million in Q1 2024 and a 60% increase compared to $31.7 million in
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. Starting at 5:00 p.m. EDT on August 8, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Thursday, August 8, 2024, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through the f
REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial Co. Ltd. (HKF) for up-front all-cash consideration of $40 million. The closing of the transaction occurred on June 26, 2024. Meitheal Pharmaceuticals, Inc. (Meitheal), a wholly owned subsidiary of HKF, will continue to commercialize YUSIMRY in the U.S. "With the divesture of YUSIMRY, Coherus reinforces its strategic focus on oncology," said Denny Lanfear, Coherus Chairman and Chief Executive Officer. "The proceeds from the sale of YUSIMRY will bolster our cash position, advance our effo
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or the Company, NASDAQ:CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024. Ms. Karachun has nearly four decades of experience leading finance, accounting, and SEC reporting functions at multi-billion-dollar global companies. Her experience includes more than 17 years at Merck, where she held positions of increasing financial management responsibility. As Global Controller at Merck, Ms. Karachun managed a global team responsible for all accou
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until July 7, 2024. Coherus Contact Information:For Investors:Jami TaylorHead of Investor [email protected]
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells (Tregs) was observed and depletion was maintained over the dosing interval, establishing proof of mechanism Preclinical data and preliminary clinical results support further evaluation of CHS-114 in combination with the anti-programmed cell death protein 1 (PD-1) antibody, toripalimab-tpzi, and other immuno-oncology (IO) agents REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS), today announced clinical data from the CHS-114, singl
REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA on Wednesday, May 29, 2024 at 12:00 p.m. Eastern Daylight Time / 9:00 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until June 26, 2024. Coherus Contact Information:For Investors:Jami TaylorHead of Investor [email protected]
– Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million term loan, with debt maturity of May 2029 – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS), today reported financial results for the quarter ended March 31, 2024 and recent business highlights: RECENT BUSINESS HIGHLIGHTS UDENYCA® RESULTS and ONBODY™ LAUNCH UPDATE UDENYCA net product sales were $42.7 million in Q1 2024, an increase of 18% compared to $36.2 million
– New $38.7 million term loan with a May 2029 maturity –– $37.5 million royalty monetization financing based on future sales of LOQTORZI® and UDENYCA® – REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS), today announced it entered into a combined term loan and product royalty financing agreement with Barings that has allowed Coherus to fully pay off the remaining $75 million of its Pharmakon Advisors term loan. This further reduces the Company's term loan debt by approximately half, with an extended loan maturity date of May 2029. "This debt and royalty financing arrangement fully repays the $75 million remaining on our prior $2
SC 13G - Coherus BioSciences, Inc. (0001512762) (Subject)
SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)
SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)
SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)
SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)
SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)
SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)
SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)
SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)
SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)
Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:
Submission status for COHERUS BIOSCIENCES INC's drug LOQTORZI (SUPPL-1) with active ingredient TORIPALIMAB-TPZI has changed to 'Approval' on 04/22/2024. Application Category: BLA, Application Number: 761240, Application Classification:
Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-15) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 12/22/2023. Application Category: BLA, Application Number: 761039, Application Classification:
Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-15) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 12/15/2023. Application Category: BLA, Application Number: 761039, Application Classification:
For Immediate Release: October 31, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Monday, the FDA provided an update from our ongoing postmarket evaluation of Essure by posting interim results from the postmarket surveillance study, after all patients have completed three years of follow up. Five-year follow-up of patients in the study i
Submission status for COHERUS BIOSCIENCES INC's drug LOQTORZI (ORIG-1) with active ingredient TORIPALIMAB-TPZI has changed to 'Approval' on 10/27/2023. Application Category: BLA, Application Number: 761240, Application Classification:
Submission status for COHERUS BIOSCIENCES INC's drug YUSIMRY (SUPPL-4) with active ingredient ADALIMUMAB-AQVH has changed to 'Approval' on 09/13/2023. Application Category: BLA, Application Number: 761216, Application Classification:
Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-13) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 03/03/2023. Application Category: BLA, Application Number: 761039, Application Classification:
Submission status for COHERUS BIOSCIENCES INC's drug YUSIMRY (SUPPL-1) with active ingredient ADALIMUMAB-AQVH has changed to 'Approval' on 02/27/2023. Application Category: BLA, Application Number: 761216, Application Classification:
Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-14) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 11/28/2022. Application Category: BLA, Application Number: 761039, Application Classification:
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday, November 6, 2024. Starting at 5:00 p.m. ET on November 6, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Wednesday, November 6, 2024, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. Starting at 5:00 p.m. EDT on August 8, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Thursday, August 8, 2024, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through the f
– Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million term loan, with debt maturity of May 2029 – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS), today reported financial results for the quarter ended March 31, 2024 and recent business highlights: RECENT BUSINESS HIGHLIGHTS UDENYCA® RESULTS and ONBODY™ LAUNCH UPDATE UDENYCA net product sales were $42.7 million in Q1 2024, an increase of 18% compared to $36.2 million
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. Starting at 5:00 p.m. EDT on May 9, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Thursday, May 9, 2024, starting at 5:00 p.m. Eastern Daylight Time To access the conference call:Dial: (800) 715-9871 (toll-free USA
REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its fourth quarter and full year 2023 financial results will be released after market close on Wednesday, March 13, 2024. Starting at 5:00 pm ET on March 13, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A replay of the webcast will be available on http://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Wednesday, March 13, 2024, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-re
– Transaction aligns to Coherus' strategic focus on oncology –– Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time – REDWOOD CITY, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced it has entered into an agreement to divest its CIMERLI® (ranibizumab-eqrn) ophthalmology franchise, inclusive of CIMERLI and its supporting commercial infrastructure, to Sandoz for upfront, all-cash consideration of $170 million plus an additional amount for CIMERLI product inventory and subject to customary working capital adjustments at the closing date. This divestiture includes Coherus' CIMERLI biologics license application, ophthal
REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS) today announced that its third quarter 2023 financial results will be released after market close on Monday, November 6, 2023. Starting at 5:00 p.m. ET on November 6, 2023, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. Conference Call Information When: Monday, November 6, 2023, starting at 5:00 p.m. Eastern TimeTo access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register.vevent.com/registe
– LOQTORZI is the first and only FDA-approved treatment for NPC – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or after platinum containing chemotherapy, irrespective of PD-L1 status – – Conference today at 4:30 p.m. Eastern Daylight Time – REDWOOD CITY, Calif. and SHANGHAI, China, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS), and Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences, HKEX: 1877; SSE: 688180) today announced that the U.S. Food and Drug Administration (FDA) approved LOQTORZI™ (toripalimab-tpzi) in combination with cisplatin and gemcitabine f
REDWOOD CITY, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS) today announced its second quarter 2023 financial results will be released after market close on Wednesday, August 02, 2023. Starting at 5:00 pm ET on August 02, 2023, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. Conference Call Information When: Wednesday, August 2nd, 2023, starting at 5:00 p.m. Eastern TimeTo access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register.vevent.com/register
– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – – Acquisition significantly advances Coherus' I-O pipeline with anti-IL-27 and anti-CCR8 clinical programs– – Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface's anticipated net cash of $20 to $25 million at closing; Surface shareholders will also receive CVRs based on potential future payments for previously partnered assets and for potential ex-US licensing – – Coherus projects $48 - 53 million of net product revenue in 2Q 2023, and affir
10-Q - Coherus BioSciences, Inc. (0001512762) (Filer)
8-K - Coherus BioSciences, Inc. (0001512762) (Filer)
8-K - Coherus BioSciences, Inc. (0001512762) (Filer)
S-8 - Coherus BioSciences, Inc. (0001512762) (Filer)
10-Q - Coherus BioSciences, Inc. (0001512762) (Filer)
8-K - Coherus BioSciences, Inc. (0001512762) (Filer)
8-K - Coherus BioSciences, Inc. (0001512762) (Filer)
8-K - Coherus BioSciences, Inc. (0001512762) (Filer)
8-K - Coherus BioSciences, Inc. (0001512762) (Filer)
8-K - Coherus BioSciences, Inc. (0001512762) (Filer)
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or the Company, NASDAQ:CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024. Ms. Karachun has nearly four decades of experience leading finance, accounting, and SEC reporting functions at multi-billion-dollar global companies. Her experience includes more than 17 years at Merck, where she held positions of increasing financial management responsibility. As Global Controller at Merck, Ms. Karachun managed a global team responsible for all accou
– Recognized biopharma commercialization and market access leader to support Coherus' strategic vision and multiple product launches – REDWOOD CITY, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced the appointment to its Board of Directors of biopharma commercialization and market access expert Michael Ryan, Pharm. D. Dr. Ryan has four decades of experience working in academia and the biopharmaceutical industry bringing high-value therapeutics to patients. Dr. Ryan's distinguished career includes most recently serving as Senior Vice President and Head for U.S. and Worldwide Value, Access, Pricing and Health Ec
- Dr. O'Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute's efforts to advance cancer immunotherapies - REDWOOD CITY, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Coherus Biosciences, Inc. (("Coherus", NASDAQ:CHRS) today announced the appointment of cancer immunotherapy leader Jill O'Donnell-Tormey, Ph.D., to its Board of Directors. Dr. O'Donnell-Tormey will also serve on the Nominating and Corporate Governance Committee of the Board of Directors. Dr. O'Donnell-Tormey is the Chief Executive Officer and Director of Scientific Affairs of the Cancer Research Institute ("CRI"), a nonprofit organization dedicated exclusively to
REDWOOD CITY, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: "CHRS", "the Company", "Coherus") today announced Rosh Dias, MD, MRCP, has been appointed Chief Medical Officer. Dr. Dias will serve as a member of the Company's executive leadership team and oversee a number of clinical functions including medical affairs, clinical operations, pharmacovigilance and clinical development. "Rosh is a terrific addition to Coherus at a time when we are sharply focused on successful execution of new product launches and on the advancement of our immuno-oncology development pipeline," said Denny Lanfear, CEO of Coherus. "A seasoned pharmaceutical executive with a demon
REDWOOD CITY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS) today announced the appointment of board-certified oncologist and seasoned healthcare executive Lee N. Newcomer, M.D., to its Board of Directors effective February 2, 2022. "We are pleased to welcome Dr. Newcomer to the Coherus Board of Directors. Lee has dedicated his career to improving care for people with cancer by applying his expertise in clinical oncology, access and reimbursement. His unique understanding of the healthcare industry will help us accelerate our strategic evolution into a leading innovative immuno-oncology company," said Denny Lanfear, CEO of C
REDWOOD CITY, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced the addition of Theresa LaVallee, Ph.D. as its Chief Development Officer. Dr. LaVallee will serve as a member of the Company's executive leadership team and oversee all regulatory matters and product development functions, reporting to Denny Lanfear, President and CEO of Coherus. "Theresa is a terrific addition to Coherus at a time when we are increasingly focused on our immuno-oncology pipeline, particularly combinations with toripalimab, our PD-1 inhibitor," said Mr. Lanfear. "She is a seasoned executive with a proven track record of success in the end-to-end discovery and de
REDWOOD CITY, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS) today announced the appointment of Ildiko Csiki, M.D., Ph.D., a leader in the field of immuno-oncology research and drug development, as Chair of its Scientific Advisory Board (SAB). With Dr. Csiki as Chair, Coherus' SAB will work closely with Coherus leadership to build a world-class immuno-oncology franchise that offers life-changing medicines to patients. In collaboration with Junshi Biosciences, Coherus is developing toripalimab, a PD-1 blocking antibody, in an extensive registrational development program for a broad range of tumor types, as well as in combination with other immu
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Blade Therapeutics, Inc. (Blade or the Company), a biopharmaceutical company committed to revolutionizing the treatment of fibrotic diseases, today announced the appointment of Jean-Frédéric Viret, Ph.D., as Chief Financial Officer (CFO) effective immediately. In his role, Dr. Viret will lead Blade’s finance and accounting functions, as well as investor relations and corporate communications. “Jean’s broad corporate finance experience and track record of building substantial value for companies will be critical as Blade continues to advance its pipeline of innovative therapies,” said Wendye Robbins, M.D., President and Chief Executive
REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointments of Alan C. Mendelson and Mark D. Stolper to its Board of Directors effective January 5, 2021. “We are excited to welcome Alan and Mark to the Coherus Board of Directors,” said Denny Lanfear, President and CEO of Coherus. “Alan is a distinguished and highly regarded legal advisor who during his long career has supported life science and technology companies through all organizational stages and diverse corporate challenges. With broad experience in investment banking, venture capital, corporate finance and operations, Mark brings to Coherus an entre
UBS downgraded Coherus BioSciences from Buy to Neutral and set a new price target of $1.50 from $4.00 previously
Robert W. Baird initiated coverage of Coherus BioSciences with a rating of Outperform and set a new price target of $11.00
Maxim Group downgraded Coherus BioSciences from Buy to Hold
Citigroup initiated coverage of Coherus BioSciences with a rating of Buy and set a new price target of $12.00
Truist initiated coverage of Coherus BioSciences with a rating of Buy and set a new price target of $24.00
UBS upgraded Coherus BioSciences from Neutral to Buy and set a new price target of $11.00
UBS initiated coverage of Coherus BioSciences with a rating of Neutral and set a new price target of $7.00
JP Morgan downgraded Coherus BioSciences from Overweight to Neutral and set a new price target of $15.00
HC Wainwright & Co. reiterated coverage of Coherus BioSciences with a rating of Buy and set a new price target of $30.00 from $36.00 previously
HC Wainwright & Co. reiterated coverage of Coherus BioSciences with a rating of Buy and set a new price target of $36.00 from $26.00 previously